Pertuzumab therapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer
- PMID: 30217673
- DOI: 10.1016/S1470-2045(18)30512-6
Pertuzumab therapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer
Comment on
-
Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study.Lancet Oncol. 2018 Oct;19(10):1372-1384. doi: 10.1016/S1470-2045(18)30481-9. Epub 2018 Sep 11. Lancet Oncol. 2018. PMID: 30217672 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous